Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon α, sunitinib, axitinib, and nivolumab therapies: a case report
Open Access
- 22 April 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Medical Case Reports
- Vol. 13 (1), 98
- https://doi.org/10.1186/s13256-019-2041-8
Abstract
There is no established treatment after failure of proven therapies for patients with metastatic renal cell carcinoma. A 66-year-old Japanese man with metastatic renal cell carcinoma became refractory to interferon α and sunitinib therapies. He started treatment with axitinib at 10 mg/day, and the dose was gradually tapered down to 4 mg/day because of intolerable adverse events. His metastatic lesions shrank; however, he could not continue due to the adverse events. He started fourth-line therapy with nivolumab; however, the metastatic lesions increased. Rechallenge with axitinib 4 mg/day was started, and the dose was reduced to 2 mg/day because of adverse events. Subsequently, the adverse events became controllable, and the metastatic lesions were maintained at reduced size. Therapeutic drug monitoring of axitinib could play an important role in the development of safe and effective therapeutic treatment and individualization of these medications.Keywords
This publication has 9 references indexed in Scilit:
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell CarcinomaThe New England Journal of Medicine, 2019
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell CarcinomaThe New England Journal of Medicine, 2019
- Novel patterns of response under immunotherapyAnnals of Oncology, 2019
- The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinomaBritish Journal of Cancer, 2018
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell CarcinomaThe New England Journal of Medicine, 2018
- Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinomaEuropean Journal of Cancer, 2015
- Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitorCancer Chemotherapy and Pharmacology, 2015
- Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic AnalysisThe Journal of Clinical Pharmacology, 2013
- Prognosis of Japanese Metastatic Renal Cell Carcinoma Patients in the Cytokine Era: A Cooperative Group Report of 1463 PatientsEuropean Urology, 2010